Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Want a daily digest of the top Nashville news?
Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.
Want a daily digest of the top Columbus news?
Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.
Want a daily digest of the top Dallas news?
Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
Photo: Spencer Platt/Getty Images
A team of scientists may have developed a new opioid alternative that kills pain while muting the addictive components, according to a new study of animal models in Science Translational Medicine published yesterday.
Why it matters: From 1999 to 2016, more than 200,000 Americans died from overdoses related to prescription opioids, my colleague Eileen Drage O'Reilly reports. Yet, these drugs remain the most effective options for treating many cases of acute or chronic pain.
- Several of the authors who are claiming success are employees of Astraea Therapeutics, which is developing the potential drug.
- Read the whole thing to understand how the science of the new compound works.
Meanwhile, the Food and Drug Administration announced yesterday that it's replacing 2014 guidance on developing new pain drugs with a more efficient, focused approach.
- Commissioner Scott Gottlieb told the Washington Postthat the 2014 guidance is overly broad and that the new agency guidance should lead to smaller clinical trials, faster approvals and quicker launches of new therapies.